Activation of abl family kinases in solid tumors.

Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92

Pathways driving the endocytosis of mutant and wild-type EGFR in cancer. Oncoscience (2014) 0.87

A phosphotyrosine switch determines the antitumor activity of ERβ. J Clin Invest (2014) 0.86

ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines. PLoS One (2015) 0.82

c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer. Oncogene (2013) 0.82

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor. Oncotarget (2016) 0.82

The Emerging Role of ABL Kinases in Solid Tumors. Trends Cancer (2015) 0.81

ABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling. Sci Signal (2016) 0.79

MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases. PLoS One (2013) 0.77

Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway. Sci Rep (2014) 0.77

Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells. Oncotarget (2016) 0.75

Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma. Oncogene (2017) 0.75

Amplification of F-Actin Disassembly and Cellular Repulsion by Growth Factor Signaling. Dev Cell (2017) 0.75

Molecular portraits of human breast tumours. Nature (2000) 94.14

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69

Lung cancer. N Engl J Med (2008) 13.49

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med (1996) 13.49

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

Integrin signalling during tumour progression. Nat Rev Mol Cell Biol (2004) 6.53

Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta (2006) 3.64

A myristoyl/phosphotyrosine switch regulates c-Abl. Cell (2003) 3.48

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest (2004) 3.44

Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature (1996) 3.37

Essential roles for the Abl and Arg tyrosine kinases in neurulation. Neuron (1998) 3.20

c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev (1999) 3.09

P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell (2006) 3.04

Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature (1997) 2.98

The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat Cell Biol (2006) 2.87

The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc. Mol Cell Biol (1989) 2.87

Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc Natl Acad Sci U S A (2001) 2.77

Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase. Proc Natl Acad Sci U S A (1998) 2.73

Interaction between ATM protein and c-Abl in response to DNA damage. Nature (1997) 2.70

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res (2006) 2.69

JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c-Abl in the apoptotic response to DNA damage. Nat Cell Biol (2005) 2.56

Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med (2001) 2.51

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia (2008) 2.44

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 2.38

Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A (1996) 2.19

c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J Biol Chem (2000) 2.17

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood (2004) 2.08

pp60c-src activation in human colon carcinoma. J Clin Invest (1989) 2.07

Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta (2009) 2.04

Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev (1995) 2.04

Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer (2002) 2.03

Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99

Autoinhibition of c-Abl. Cell (2002) 1.93

ABL tyrosine kinases: evolution of function, regulation, and specificity. Sci Signal (2010) 1.91

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.88

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 1.79

Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene (2007) 1.78

An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Res (2011) 1.75

The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein and a physiological inhibitor of c-Abl tyrosine kinase activity. Genes Dev (1997) 1.72

Inhibition of c-Abl tyrosine kinase activity by filamentous actin. J Biol Chem (2001) 1.71

Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation. Nat Cell Biol (2004) 1.69

A critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsal-wave formation. Curr Biol (2007) 1.69

Inhibition of cell migration by Abl family tyrosine kinases through uncoupling of Crk-CAS complexes. J Biol Chem (2001) 1.65

The nuclear tyrosine kinase c-Abl negatively regulates cell growth. Cell (1994) 1.62

The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab (2003) 1.61

ABL1 fusion genes in hematological malignancies: a review. Eur J Haematol (2011) 1.61

The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J (1996) 1.60

Tumor progression: Small GTPases and loss of cell-cell adhesion. Bioessays (2003) 1.58

RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol (2005) 1.55

Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55

Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature (1997) 1.54

Integrin signaling through Arg activates p190RhoGAP by promoting its binding to p120RasGAP and recruitment to the membrane. Mol Biol Cell (2006) 1.54

A new link between the c-Abl tyrosine kinase and phosphoinositide signalling through PLC-gamma1. Nat Cell Biol (2003) 1.53

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res (2008) 1.52

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia (2007) 1.52

The Abl-related gene (Arg) requires its F-actin-microtubule cross-linking activity to regulate lamellipodial dynamics during fibroblast adhesion. J Cell Biol (2004) 1.51

WAVE3-mediated cell migration and lamellipodia formation are regulated downstream of phosphatidylinositol 3-kinase. J Biol Chem (2005) 1.50

Imatinib mesylate in cutaneous melanoma. J Invest Dermatol (2004) 1.48

Evidence for regulation of the human ABL tyrosine kinase by a cellular inhibitor. Proc Natl Acad Sci U S A (1991) 1.46

c-Abl-mediated phosphorylation of WAVE3 is required for lamellipodia formation and cell migration. J Biol Chem (2007) 1.46

A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo. Cancer Res (2007) 1.45

Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res (2011) 1.43

Abl tyrosine kinases regulate cell-cell adhesion through Rho GTPases. Proc Natl Acad Sci U S A (2007) 1.43

MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J (2006) 1.42

c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J (2002) 1.41

Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. Nature (1996) 1.39

Abl tyrosine kinase regulates endocytosis of the epidermal growth factor receptor. J Biol Chem (2006) 1.38

Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem (1998) 1.37

c-Abl, Lamellipodin, and Ena/VASP proteins cooperate in dorsal ruffling of fibroblasts and axonal morphogenesis. Curr Biol (2010) 1.34

Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer (2003) 1.33

Retracted cAbl tyrosine kinase mediates reactive oxygen species- and caveolin-dependent AT1 receptor signaling in vascular smooth muscle: role in vascular hypertrophy. Circ Res (2005) 1.29

Activated c-Abl tyrosine kinase in malignant solid tumors. Oncogene (2008) 1.28

A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid (2010) 1.26

c-Abl phosphorylates Dok1 to promote filopodia during cell spreading. J Cell Biol (2004) 1.26

Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells. Proc Natl Acad Sci U S A (1998) 1.25

Abl kinases regulate autophagy by promoting the trafficking and function of lysosomal components. J Biol Chem (2008) 1.25

Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Clin Cancer Res (2008) 1.24

Transforming growth factor beta activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures. J Biol Chem (2006) 1.24

Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo. Mol Cell Biol (1998) 1.23

Regulation of prostate cancer progression by galectin-3. Am J Pathol (2009) 1.21

Caspase-dependent cleavage of c-Abl contributes to apoptosis. Mol Cell Biol (2003) 1.20

Abl kinases are required for invadopodia formation and chemokine-induced invasion. J Biol Chem (2010) 1.20

Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene (2003) 1.20

Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J (2009) 1.20

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat (2005) 1.19

Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. Mol Biol Cell (2008) 1.18

Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene (2010) 1.16

Cytoskeletal protein PSTPIP1 directs the PEST-type protein tyrosine phosphatase to the c-Abl kinase to mediate Abl dephosphorylation. Mol Cell (2000) 1.16

Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene (2007) 1.15

Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets (2011) 1.15

c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene (2011) 1.15

Cellular responses to DNA damage. Curr Opin Cell Biol (1998) 1.14

Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol (2004) 1.14

A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mol Cell (2006) 1.14

Comparative tyrosine-kinase profiles in colorectal cancers: enhanced arg expression in carcinoma as compared with adenoma and normal mucosa. Int J Cancer (1999) 1.12

Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway. Curr Biol (2001) 1.12

Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res (2006) 2.69

Abl tyrosine kinases are required for infection by Shigella flexneri. EMBO J (2003) 1.59

MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines. Cancer Chemother Pharmacol (2009) 1.56

SHP-2 is a novel target of Abl kinases during cell proliferation. J Cell Sci (2008) 1.01

Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-κB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One (2013) 0.94

Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal (2009) 0.93

Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia (2010) 0.92

STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochem Pharmacol (2009) 0.88